For the year ending 2025-12-31, NUVB had $128,363K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -204,627 |
| Stock-based compensation | 35,894 |
| Depreciation and amortization | 1,739 |
| Non-cash lease expense | 275 |
| Non-cash interest on revenue interest financing agreement | -10,138 |
| Amortization of issuance costs | 662 |
| Change in fair value of warrant liability | 812 |
| Amortization of premium and discounts on marketable securities | 5,284 |
| Realized loss (gain) on marketable securities | 5 |
| Net loss on disposal of property and equipment | -33 |
| Unrealized foreign currency transaction loss | 1,085 |
| Acquired in-process research and development | 0 |
| Accounts receivable | 3,354 |
| Prepaid expenses and other current assets | 4,265 |
| Inventory | 11,411 |
| Interest receivable on marketable securities | -285 |
| Other non-current assets | 846 |
| Accounts payable | 3,131 |
| Contract liabilities | 7,869 |
| Accrued expenses | 12,350 |
| Net cash used in operating activities | -173,427 |
| Cash acquired from anheart acquisition | 0 |
| Transaction costs related to anheart acquisition | 0 |
| Purchases of marketable securities | 354,416 |
| Proceeds from sale of marketable securities | 462,290 |
| Purchases of property and equipment | 354 |
| Cash paid for capitalized market approval intangibles | 8,000 |
| Net cash provided by investing activities | 99,520 |
| Proceeds from borrowings, net of issuance costs | 60,102 |
| Proceeds from revenue interest financing agreement | -150,000 |
| Payments on borrowings | 11,899 |
| Payments on debt issuance costs | 6,596 |
| Payments on finance agreement | 493 |
| Proceeds from issuance of common stock under espp | -1,310 |
| Proceeds from exercises of options | 10,111 |
| Net cash provided by financing activities | 202,535 |
| Effect of foreign exchange rate changes on cash and cash equivalents | -265 |
| Net decrease in cash and cash equivalents | 128,363 |
| Cash and cash equivalents, beginning of the period | 35,723 |
| Cash and cash equivalents, end of the period | 164,086 |
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)